期刊
CONTEMPORARY CLINICAL TRIALS
卷 63, 期 -, 页码 40-50出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.cct.2017.02.007
关键词
Clinical trials; Interaction; Predictive biomarker; Scale; Time to event data
资金
- National Cancer Institute, USA [R01 CA137420, R01 CM 97402, P30 CA008748]
- Clinical and Translational Science Centerat Weill Cornell Medical College, New York, USA [UL1RR024996]
Clinical and epidemiological studies of anticancer therapies increasingly seek to identify predictive biomarkers to obtain insights into variation in treatment benefit. For time to event endpoints, a predictive biomarker is typically assessed using the interaction between the biomarker and treatment in a proportional hazards model. Interactions are contrasts of summaries of outcomes and depend upon the choice of the outcome scale. In this paper, we investigate interaction contrasts under three scales - the natural logarithm of hazard ratio, the natural logarithm of survival probability, and survival probability at a pre-specified time. We illustrate that we can have a non-zero interaction on survival or logarithm of survival probability scales even when there is no interaction on the logarithm of hazard ratio scale. Since survival probabilities have clinically useful interpretation and are easier to convey to patients than hazard ratios, we recommend evaluating a predictive biomarker using survival probabilities. We provide empirical illustration of the three scales of interaction for evaluating a predictive biomarker using reconstructed data from a published melanoma study. (C) 2017 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据